• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SkinMedica® Celebrates 25 Years of Empowering Radiant Skin

    6/6/24 8:30:00 AM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ABBV alert in real time by email
    • Allē Members Can Celebrate with Double Points and Enter for a Chance to Win $5,000

    IRVINE, Calif., June 6, 2024 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE:ABBV), the makers of BOTOX® Cosmetic (onabotulinumtoxinA), is celebrating 25 years of SkinMedica®. To mark this milestone anniversary, Allē Members who purchase SkinMedica® products at a participating Allē Health Care Provider or SkinMedica.com from June 1 to June 25, 2024 can earn double points* and enter for a chance to win $5,000.**

    "For 25 years, SkinMedica® has been delivering scientifically based skincare to patients and helping them to unlock the potential to have beautiful skin," said Jasson Gilmore, Senior Vice President of U.S. Aesthetics at Allergan Aesthetics. "We want to thank everyone who is a part of the SkinMedica® family from its founders to our scientists, our employees, our customers and of course, everyone who uses SkinMedica®!"

    Since 1999, SkinMedica® has developed high-quality, science-backed formulas that deliver visible results. The initial product launch of Dermal Repair Cream was soon followed by the groundbreaking TNS Recovery Complex®, TNS Essential Serum®, and TNS® Advanced+ Serum, establishing the brand as a fixture in the industry. Throughout its evolution, SkinMedica® would continue to introduce new, innovative formulations to SkinMedica® loyalists and newcomers for years to come.

    "Twenty-five years ago, we founded SkinMedica® with a vision—to create a skincare line that's both scientific and luxurious, yet easy to use," reflected Dr. Kimberly Butterwick, a double board-certified dermatologist and SkinMedica® co-founder. "Our breakthrough TNS® product, developed through a unique process that harnessed growth factors, transformed SkinMedica® from a startup into a brand known for innovation and excellence."

    "Beautiful skin is timeless," Dr. Butterwick continues. "For 25 years, SkinMedica® has helped people feel more confident in their own skin, and I continue to count on them to provide science-based solutions to address my patients' key skincare concerns. As we celebrate this anniversary, I look forward to seeing how SkinMedica® continues to innovate and provide exceptional skincare in the next 25 years."

    Follow @SkinMedica on Instagram to stay updated on exciting 25th anniversary promotions this month. Use the hashtag #25YearsOfSkinMedica to join in on the celebrations and share your SkinMedica® skincare journey. To learn more about the SkinMedica® range of exceptional products, visit SkinMedica.com.

    *Terms and conditions apply to the double points offer.

    **NO PURCHASE NECESSARY for sweepstakes. Open to Allē Members in 50 U.S./D.C.; age 18+ (19+ in AL & NE; 21+ in MS). Starts at 12:00:01 AM PT on 6/1/24; ends at 11:59:59 PM PT on 6/25/24. Allē Members must be logged into their Allē account if purchasing from SkinMedica.com or a Brilliant Connections™ online retailer for such purchases to be eligible for this promotion. See full Official Rules for all details and how to enter without purchase at https://alle.com/sweeps/skinmedica-25th-celebration. Sponsor: Allergan, Inc.

    About Allergan Aesthetics

    At Allergan Aesthetics, an AbbVie company, we develop, manufacture, and market a portfolio of leading aesthetics brands and products. Our aesthetics portfolio includes facial injectables, body contouring, plastics, skin care, and more. Our goal is to consistently provide our customers with innovation, education, exceptional service, and a commitment to excellence, all with a personal touch. For more information, visit www.allerganaesthetics.com

    About AbbVie

    AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas – immunology, oncology, neuroscience, and eye care – and products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on LinkedIn, Facebook, Instagram, X (formerly Twitter), and YouTube.

    Forward-Looking Statements

    Some statements in this news release are, or may be considered, forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. The words "believe," "expect," "anticipate," "project" and similar expressions and uses of future or conditional verbs, generally identify forward-looking statements. AbbVie cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those expressed or implied in the forward-looking statements. Such risks and uncertainties include, but are not limited to, challenges to intellectual property, competition from other products, difficulties inherent in the research and development process, adverse litigation or government action, and changes to laws and regulations applicable to our industry. Additional information about the economic, competitive, governmental, technological and other factors that may affect AbbVie's operations is set forth in Item 1A, "Risk Factors," of AbbVie's 2023 Annual Report on Form 10-K, which has been filed with the Securities and Exchange Commission, as updated by its subsequent Quarterly Reports on Form 10-Q. AbbVie undertakes no obligation, and specifically declines, to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.

    BOTOX® COSMETIC IMPORTANT SAFETY INFORMATION AND APPROVED USES

    Approved Uses

    BOTOX® Cosmetic is a prescription medicine that is injected into muscles and used to temporarily improve the look of moderate to severe forehead lines, crow's feet lines, and frown lines between the eyebrows in adults.

    IMPORTANT SAFETY INFORMATION

    BOTOX® Cosmetic may cause serious side effects that can be life threatening. Get medical help right away if you have any of these problems any time (hours to weeks) after injection of BOTOX® Cosmetic:

    • Problems swallowing, speaking, or breathing, due to weakening of associated muscles, can be severe and result in loss of life. You are at the highest risk if these problems are pre-existing before injection. Swallowing problems may last for several months.
    • Spread of toxin effects. The effect of botulinum toxin may affect areas away from the injection site and cause serious symptoms including: loss of strength and all-over muscle weakness, double vision, blurred vision and drooping eyelids, hoarseness or change or loss of voice, trouble saying words clearly, loss of bladder control, trouble breathing, and trouble swallowing.

    BOTOX® Cosmetic dosing units are not the same as, or comparable to, any other botulinum toxin product.

    There has not been a confirmed serious case of spread of toxin effect when BOTOX® Cosmetic has been used at the recommended dose to treat frown lines, crow's feet lines, and/or forehead lines.

    BOTOX® Cosmetic may cause loss of strength or general muscle weakness, vision problems, or dizziness within hours to weeks of taking BOTOX® Cosmetic. If this happens, do not drive a car, operate machinery, or do other dangerous activities.

    Serious and/or immediate allergic reactions have been reported. They include: itching, rash, red itchy welts, wheezing, asthma symptoms, or dizziness or feeling faint. Get medical help right away if you are wheezing or have asthma symptoms, or if you become dizzy or faint.

    Do not receive BOTOX® Cosmetic if you: are allergic to any of the ingredients in BOTOX® Cosmetic (see Medication Guide for ingredients); had an allergic reaction to any other botulinum toxin product such as Myobloc® (rimabotulinumtoxinB), Dysport® (abobotulinumtoxinA), or Xeomin® (incobotulinumtoxinA); have a skin infection at the planned injection site.

    Tell your doctor about all your muscle or nerve conditions, such as ALS or Lou Gehrig's disease, myasthenia gravis, or Lambert-Eaton syndrome, as you may be at increased risk of serious side effects including difficulty swallowing and difficulty breathing from typical doses of BOTOX® Cosmetic.

    Tell your doctor about all your medical conditions, including: plans to have surgery; had surgery on your face; have trouble raising your eyebrows; drooping eyelids; any other abnormal facial change; are pregnant or plan to become pregnant (it is not known if BOTOX® Cosmetic can harm your unborn baby); are breast-feeding or plan to (it is not known if BOTOX® Cosmetic passes into breast milk).

    Tell your doctor about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Using BOTOX® Cosmetic with certain other medicines may cause serious side effects. Do not start any new medicines until you have told your doctor that you have received BOTOX® Cosmetic in the past. 

    Tell your doctor if you have received any other botulinum toxin product in the last 4 months; have received injections of botulinum toxin such as Myobloc®, Dysport®, or Xeomin® in the past (tell your doctor exactly which product you received); have recently received an antibiotic by injection; take muscle relaxants; take an allergy or cold medicine; take a sleep medicine; take aspirin-like products or blood thinners.

    Other side effects of BOTOX® Cosmetic include: dry mouth; discomfort or pain at the injection site; tiredness; headache; neck pain; and eye problems: double vision, blurred vision, decreased eyesight, drooping eyelids and eyebrows, swelling of your eyelids and dry eyes.

    For more information refer to the Medication Guide or talk with your doctor. 

    To report a side effect, please call Allergan at 1-800-678-1605.

    Please see BOTOX® Cosmetic full Product Information including Boxed Warning and Medication Guide.

    SkinMedica® Important Information 

    Most SkinMedica® products are intended to meet the FDA's definition of a cosmetic product, an article applied to the human body to cleanse, beautify, promote attractiveness, and alter appearances. These SkinMedica® products are not intended to be drug products that diagnose, treat, cure, or prevent any disease or condition. These products have not been approved by the FDA and the statements have not been evaluated by the FDA. 

    For more information, please talk to your provider or visit SkinMedica.com. To report an adverse reaction, please call Allergan at 1-800-433-8871. 

    Allergan Aesthetics (PRNewsfoto/AbbVie)

     

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/skinmedica-celebrates-25-years-of-empowering-radiant-skin-302165354.html

    SOURCE AbbVie

    Get the next $ABBV alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ABBV

    DatePrice TargetRatingAnalyst
    8/12/2025$231.00Overweight
    Piper Sandler
    8/7/2025$214.00Neutral → Outperform
    Daiwa Securities
    5/14/2025$205.00Buy → Neutral
    Citigroup
    4/22/2025$210.00Overweight
    Cantor Fitzgerald
    12/10/2024$191.00Neutral
    BofA Securities
    12/5/2024$180.00Outperform → Neutral
    Daiwa Securities
    11/22/2024$206.00Market Perform → Outperform
    Leerink Partners
    11/15/2024$205.00Outperform
    Wolfe Research
    More analyst ratings

    $ABBV
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Piper Sandler resumed coverage on AbbVie with a new price target

    Piper Sandler resumed coverage of AbbVie with a rating of Overweight and set a new price target of $231.00

    8/12/25 8:00:24 AM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    AbbVie upgraded by Daiwa Securities with a new price target

    Daiwa Securities upgraded AbbVie from Neutral to Outperform and set a new price target of $214.00

    8/7/25 7:30:45 AM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    AbbVie downgraded by Citigroup with a new price target

    Citigroup downgraded AbbVie from Buy to Neutral and set a new price target of $205.00

    5/14/25 8:54:15 AM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABBV
    SEC Filings

    View All

    SEC Form 144 filed by AbbVie Inc.

    144 - AbbVie Inc. (0001551152) (Subject)

    8/12/25 7:22:19 PM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 144 filed by AbbVie Inc.

    144 - AbbVie Inc. (0001551152) (Subject)

    8/8/25 5:03:05 PM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by AbbVie Inc.

    10-Q - AbbVie Inc. (0001551152) (Filer)

    8/4/25 3:17:04 PM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABBV
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    AbbVie Completes Acquisition of Capstan Therapeutics

    Acquisition adds a potential first-in-class in vivo targeted lipid nanoparticle (tLNP) anti-CD19 CAR-T therapy candidate for B cell-mediated autoimmune diseases as well as a proprietary tLNP platform designed to deliver RNA payloads, such as mRNA, capable of engineering specific cell types in vivoNORTH CHICAGO, Ill., Aug. 19, 2025 /PRNewswire/ -- AbbVie (NYSE:ABBV) announced today that it has completed its acquisition of Capstan Therapeutics. With the completion of the acquisition, Capstan is now a part of AbbVie. Capstan's lead asset CPTX2309, currently in Phase 1 for the treatment of B cell-mediated autoimmune diseases, is a tLNP that generates CD19-specific, CD8+ in vivo CAR-T cells. The

    8/19/25 8:55:00 AM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SkinMedica® Unveils Its Newest Hydration Hero

    By the makers of BOTOX® Cosmetic (onabotulinumtoxinA), SkinMedica® introduces a next generation amino acid–based cleanser: HA5® Hydra Collagen Hydrating Foaming Cleanser.IRVINE, Calif, Aug. 19, 2025 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announced today the newest addition to the SkinMedica® HA5® Hydra Collagen portfolio. Featuring the brand's proprietary HA5® Hydra Collagen Complex – a blend of five forms of hyaluronic acid and vegan hydra collagen – the HA5® Hydra Collagen Hydrating Foaming Cleanser delivers instant hydration while providing a thorough cleanse, leaving skin feeling clean, calm, and cloud-soft. "As leaders in aesthetic medicine, innovation is a

    8/19/25 8:00:00 AM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    AbbVie Announces $195 Million Investment to Expand Active Pharmaceutical Ingredient Manufacturing in the U.S.

    New $195 million facility will further enhance AbbVie's active pharmaceutical ingredient (API) production capacity and capabilities in the U.S.Expansion is part of AbbVie's previously announced commitment to invest more than $10 billion of capital in the U.S. over the next decadeConstruction will begin in fall 2025 with the site expected to be fully operational in 2027Furthers AbbVie's long-term commitment to the U.S. expanding the company's North Chicago workforce and critical manufacturing capabilitiesNORTH CHICAGO, Ill., Aug. 12, 2025 /PRNewswire/ -- AbbVie (NYSE:ABBV) today announced a $195 million investment in its North Chicago, Illinois manufacturing plant to expand domestic active ph

    8/12/25 1:00:00 PM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABBV
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for VYALEV issued to ABBVIE INC

    Submission status for ABBVIE INC's drug VYALEV (ORIG-1) with active ingredient FOSCARBIDOPA AND FOSLEVODOPA has changed to 'Approval' on 10/16/2024. Application Category: NDA, Application Number: 216962, Application Classification: Type 3 - New Dosage Form and Type 4 - New Combination

    10/18/24 4:38:13 AM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for VYALEV issued to ABBVIE INC

    Submission status for ABBVIE INC's drug VYALEV (ORIG-1) with active ingredient FOSCARBIDOPA AND FOSLEVODOPA has changed to 'Approval' on 10/16/2024. Application Category: NDA, Application Number: 216962, Application Classification: Type 3 - New Dosage Form

    10/17/24 1:29:31 PM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for SKYRIZI issued to ABBVIE INC

    Submission status for ABBVIE INC's drug SKYRIZI (SUPPL-7) with active ingredient RISANKIZUMAB-RZAA has changed to 'Approval' on 06/18/2024. Application Category: BLA, Application Number: 761262, Application Classification:

    6/21/24 4:38:17 AM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABBV
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP, CHIEF OPERATIONS OFFICER Saleki-Gerhardt Azita sold $8,407,055 worth of shares (42,370 units at $198.42) and exercised 42,370 shares at a strike of $54.86 (SEC Form 4)

    4 - AbbVie Inc. (0001551152) (Issuer)

    8/14/25 5:00:06 PM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    EVP, CHIEF BUS/STRAT OFFICER Donoghoe Nicholas sold $2,639,253 worth of shares (13,295 units at $198.51), decreasing direct ownership by 19% to 58,247 units (SEC Form 4)

    4 - AbbVie Inc. (0001551152) (Issuer)

    8/7/25 5:00:06 PM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: New insider Crum Demetris D claimed ownership of 7,048 shares (SEC Form 3)

    3/A - AbbVie Inc. (0001551152) (Issuer)

    7/30/25 5:00:26 PM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABBV
    Financials

    Live finance-specific insights

    View All

    AbbVie Reports Second-Quarter 2025 Financial Results

    Reports Second-Quarter Diluted EPS of $0.52 on a GAAP Basis, a Decrease of 32.5 Percent; Adjusted Diluted EPS of $2.97, an Increase of 12.1 Percent; These Results Include an Unfavorable Impact of $0.42 Per Share Related to Acquired IPR&D and Milestones Expense   Delivers Second-Quarter Net Revenues of $15.423 Billion, an Increase of 6.6 Percent on a Reported Basis or 6.5 Percent on an Operational Basis Second-Quarter Global Net Revenues from the Immunology Portfolio Were $7.631 Billion, an Increase of 9.5 Percent on a Reported Basis, or 9.2 Percent on an Operational Basis; Global Skyrizi Net Revenues Were $4.423 Billion; Global Rinvoq Net Revenues Were $2.028 Billion; Global Humira Net Reven

    7/31/25 7:44:00 AM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    AbbVie to Host Second-Quarter 2025 Earnings Conference Call

    NORTH CHICAGO, Ill., June 30, 2025 /PRNewswire/ -- AbbVie (NYSE:ABBV) will announce its second-quarter 2025 financial results on Thursday, July 31, 2025, before the market opens. AbbVie will host a live webcast of the earnings conference call at 8 a.m. Central time. It will be accessible through AbbVie's Investor Relations website at investors.abbvie.com. An archived edition of the session will be available later that day. About AbbVie AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas –

    6/30/25 8:00:00 AM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    AbbVie Declares Quarterly Dividend

    NORTH CHICAGO, Ill., June 20, 2025 /PRNewswire/ -- The board of directors of AbbVie Inc. (NYSE:ABBV) today declared a quarterly cash dividend of $1.64 per share.  The cash dividend is payable August 15, 2025, to stockholders of record at the close of business on July 15, 2025. Since the company's inception in 2013, AbbVie has increased its dividend by 310 percent. AbbVie is a member of the S&P Dividend Aristocrats Index, which tracks companies that have annually increased their dividend for at least 25 consecutive years. About AbbVie AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tom

    6/20/25 8:00:00 AM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABBV
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by AbbVie Inc. (Amendment)

    SC 13G/A - AbbVie Inc. (0001551152) (Subject)

    2/13/24 4:55:55 PM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by AbbVie Inc. (Amendment)

    SC 13G/A - AbbVie Inc. (0001551152) (Subject)

    1/25/24 4:59:27 PM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by AbbVie Inc. (Amendment)

    SC 13G/A - AbbVie Inc. (0001551152) (Subject)

    2/9/23 10:54:46 AM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABBV
    Leadership Updates

    Live Leadership Updates

    View All

    AbbVie Appoints CEO Robert A. Michael as Chairman of the Board of Directors

    Richard A. Gonzalez to retire from the board of directors effective July 1, 2025NORTH CHICAGO, Ill., Feb. 14, 2025 /PRNewswire/ -- AbbVie (NYSE:ABBV) today announced that its board of directors has unanimously elected chief executive officer (CEO) Robert A. Michael to assume the additional position of chairman, effective July 1, 2025. He will succeed Richard A. Gonzalez, who formerly served as AbbVie's CEO and has been chairman since the Company's formation in 2013. "I want to extend my heartfelt gratitude to Rick for his remarkable leadership and dedicated service," said Roxanne S. Austin, lead independent director. "The board and I have complete confidence in Rob, and we are fortunate to

    2/14/25 7:40:00 AM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PureTech Founded Entity Seaport Therapeutics Names Lauren White as Chief Financial Officer

    Former ImmunoGen CFO will join Seaport to steer capital financing strategy, accounting, FP&A and investor relations PureTech Health plc (NASDAQ:PRTC, LSE: PRTC)) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company, noted that its Founded Entity, Seaport Therapeutics, ("Seaport") a biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and team, today announced the appointment of Lauren White as Chief Financial Officer. An accomplished biotech financial executive, Ms. White most recently served as the Chief Financial Officer at ImmunoGen (NASDAQ:IMGN) prior to its acquisition by AbbVie (NYSE:ABBV) for $10.1 billion in 2024. T

    11/5/24 7:05:00 AM ET
    $ABBV
    $CCCC
    $IMGN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    Seaport Therapeutics Names Lauren White as Chief Financial Officer

    Former ImmunoGen CFO will join Seaport to steer capital financing strategy, accounting, FP&A and investor relations Seaport Therapeutics ("Seaport or the "Company"), a clinical-stage biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and team, today announced the appointment of Lauren White as Chief Financial Officer. An accomplished biotech financial executive, Ms. White most recently served as the Chief Financial Officer at ImmunoGen (NASDAQ:IMGN) prior to its acquisition by AbbVie (NYSE:ABBV) for $10.1 billion in 2024. "I am so pleased to welcome Lauren as our CFO as we progress our clinical-stage pipeline of therapeutics for the treatme

    11/5/24 7:00:00 AM ET
    $ABBV
    $CCCC
    $IMGN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)